Treatment of Sarcoma with Lymph Node Spread

Introduction to Sarcoma Treatment

The European Society for Medical Oncology recommends aggressive multimodal treatment for adult soft tissue sarcoma with regional lymph node metastases, including wide surgical excision of both the primary tumor and involved lymph nodes, combined with adjuvant radiotherapy and chemotherapy for chemosensitive histologic subtypes, recognizing this represents likely systemic disease with poor prognosis 1, 2, 3

Regional lymph node metastases occur in only approximately 4% of adult soft tissue sarcomas and constitute a strong adverse prognostic factor, with the presence of lymph node metastases signaling likely systemic disease, not truly localized disease amenable to "adjuvant" therapy 1, 2, 3
The presence of lymph node metastases indicates lymphatic dissemination, which must be distinguished from soft tissue metastases that happen to involve lymph nodes 1, 2, 3

Wide excision of the primary tumor and involved lymph nodes is the cornerstone of treatment, though mutilating surgery should be avoided given the poor prognosis of these patients, and lymph node dissection should target clinically or radiologically evident nodal disease 1, 2, 3
Plastic repairs and vascular grafting should be utilized as needed to achieve adequate resection 1

Adjuvant radiotherapy is standard treatment for sarcoma with lymph node spread and should be administered to both the primary site and nodal basin, with postoperative radiotherapy: 50-60 Gy in 1.8-2 Gy fractions, and preoperative radiotherapy: 50 Gy in standard fractionation 1, 2, 3
Radiation improves local control but does not improve overall survival 1, 4

Chemotherapy should be administered for chemosensitive histologic subtypes, and may be given preoperatively or postoperatively, with doxorubicin-based regimens being most commonly used for chemosensitive histologies 1, 2, 3
Regional hyperthermia combined with systemic chemotherapy showed local and disease-free survival advantage in one large randomized phase III trial for high-risk patients 1, 2, 3

Isolated hyperthermic limb perfusion with TNF-α plus melphalan is an option for extremity-confined tumors, though this has no impact on systemic control and should be combined with other modalities 1, 2, 3
Elevated serum lactate dehydrogenase (LDH) at presentation is an adverse prognostic factor in sarcomas and is associated with metastatic disease, high histological grade, and worse disease-specific survival 5, 6

Do not perform extended lymph node dissection for clinically negative nodes (cN0) in soft tissue sarcoma, as there is no survival benefit and only staging value 1, 2, 3
Do not treat this as truly "adjuvant" therapy, as the presence of lymph node metastases indicates systemic disease with poor prognosis requiring aggressive multimodal treatment 1, 2
Avoid mutilating surgery given the systemic nature and poor prognosis, with functional preservation being important 1, 2, 3